Identification of functional domains in the envelope glycoproteins (gp120 and gp4l) of human immunodeficiency virus type 1 (HIV-1) is important for the development of a vaccine for AIDS. A site in the C-terminal region of gpl20 has been shown by Lasky et al. (17) to be critical for virus binding to its receptor, CD4. Additional studies by Cordonnier et al. (4) also showed that several mutations within this region of gpl20 resulted in loss of CD4 binding. Interestingly, mouse monoclonal antibodies directed against this putative binding site are either nonneutralizing (17) or only variably neutralizing (30) against HIV-1 in vitro. Several other antibody neutralization domains have been determined (2, 7, 9, 11, 12, 14, 15, 18, 24, 25, 27, 28) , among which is the loop structure in the third variable region of gp120 (V3 loop) that is believed to be the principal neutralization domain (9, 14, 15, 18, 24, 25, 27) . However, probably related to its sequence heterogeneity among isolates, the V3 loop induces type-specific neutralizing antibodies (9, 14, 15, 18, 24, 25, 27, 28) , which do not account for the broad virus-neutralizing activity detected in the sera of most infected persons (1, 12, 33) . Such broadly neutralizing antibodies may be directed against a conserved site in gp4l (2, 7) or against conformational epitopes on gpl20, as was recently shown by Haigwood et al. (10) . We now present data on a human monoclonal antibody which identifies a previously unrecognized, conformation-dependent epitope on gp120 important for both HIV-1 neutralization and CD4 binding.
A human monoclonal antibody, I5e (originally designated N70-1.5e), was derived by Epstein-Barr virus transformation of B cells from an asymptomatic person seropositive for antibodies to HIV-1 (26) . This antibody is an immunoglobulin Gl (IgGl) with kappa light chains and is specific for the gpl20 of all 11 HIV-1 isolates initially tested by enzyme immunoassays and Western immunoblots (26) . In a radioimmunoprecipitation assay described previously (11, 12, 30) , 15e was reactive with gpl20 and/or its precursor gp160 from * Corresponding author.
HIV-1 isolates IIIB, MN, and Z84 but not with isolates RF and AL (Fig. 1A) . 15e did not react with the envelope glycoprotein of the LAV-2ROD strain (3) of HIV-2 by either enzyme immunoassay or radioimmunoprecipitation assay (data not shown).
I5e was also tested for neutralizing activity against multiple laboratory and primary HIV-1 isolates with an assay described previously (11, 12, 30) . As shown in Fig. 2A Fig. 2 suggest that ISe is an HIV-1-neutralizing human monoclonal antibody which has broad specificity.
We next examined ISe for its ability to compete with CD4 for gpl20/gpl60 binding, as this is one potential mechanism for the HIV-1-neutralizing activity. In the experiment shown in Fig. 1B , increasing doses of soluble CD4 (sCD4) (8) were added to a metabolically labeled lysate of HIV-1 prior to immunoprecipitation. sCD4 competed with ISe in a dosedependent manner, suggesting that the epitope on gpl20 for this human monoclonal antibody may be on the surface, which makes contact with CD4. This observation was confirmed by a quantitative competition enzyme immunoassay described by Moore et al. (20, 21) , with recombinant gpl20 captured indirectly onto solid-phase and sCD4. As shown in Fig. 3 , ISe blocked gpl20-sCD4 binding in a dose-dependent manner. In fact, it was more potent in doing so than two mouse anti-gpl20 monoclonal antibodies, G3-536 and G3-537 (30), which we have previously mapped to the putative CD4-binding site described by Lasky et al. (17) . The amount of I5e, G3-536, and G3-537 required to reduce gpl20-sCD4 binding by 50% was 70, 2,500, and 200 ng/ml, respectively. The greater ability of ISe in blocking gpl20-sCD4 interaction is not due to a greater affinity for gpl20, since ISe and G3-536 have similar binding constants for gpl20 (50% maximal binding to gpl20 was observed at 47 ng/ml for ISe and at 86 ng/ml for G3-536; data not shown).
Given ISe's ability to neutralize HIV-1 and to block gpl20-sCD4 binding, attempts were made to localize its epitope by peptide enzyme immunoassays. Results from such studies are schematically summarized in Fig. 4 . ISe reacted with native gpl20 and recombinant gpl20 expressed in Chinese hamster ovary (CHO) cells. However, this anti--body did not react with unglycosylated gpl20 made by Escherichia coli or Saccharomyces cerevisiae. In addition, ISe did not recognize recombinant envelope fragments (PE3, PB1, and pEnv9) produced in E. coli. Furthermore, there was not reactivity with a panel of synthetic peptides representing different regions of gpl20, including the second conserved domain (11) , the V3 neutralization loop (9, 14, 15, 18, 24, 25, 27, 28) , and the putative CD4-binding site defined by Lasky et al. (17) . Together, these findings suggest that the epitope of 15e is probably not composed of a linear sequence. Instead, the epitope is likely to be conformation or carbohydrate dependent or both.
The conformational nature of the ISe epitope was con- (11, 12, 30) (0). The neutralization assay was performed as described previously (11, 12, 30) , with the p24 antigen concentration in the supermatant used as the indicator of virus infection. (B) ISe neutralization of 10 primary HIV-1 isolates. These viruses were isolated from patients in short-term cultures of normal peripheral blood mononuclear cells. Virus titers were determined by serial dilutions. The virus stains were assayed for susceptibility to ISe neutralization with 50 50% tissue culture-infective doses of virus and a method already described (5) performed by the procedure of Moore et al. (20, 21 (17) . The peptide immunoassays were performed as outlined previously (30) , and the results are summarized on the left. Native and recombinant CHO gp120 were gifts of G. Robey (Fig.5B) . Interestingly, the latter serum samples had crossneutralizing antibodies against the IIIB laboratory isolate, with titers ranging from 1:8 to 1:64. In contrast, the two sera from AIDS cases which did not compete with ISe failed to neutralize IIIB even at a 1:4 dilution (data not shown).
We next tested sequential serum samples from seven patients in the first few months following initial HIV-1 infection and seroconversion (29; unpublished data). As shown in Fig.5C , in the first 2 months after seroconversion, patients lack antibodies which compete with ISe, although all had anti-gp120 antibodies as determined by radioimmunoprecipitation assays (11, 12, 30) . In one patient, there was evidence that ISe-competing antibodies began to appear at 6 months. This led us to study serum samples from three patients from whom multiple sequential blood samples were obtained in the first 2 years following seroconversion (13) .
Each serum sample was assayed for its anti-gp120 antibody reactivity, ability to compete with ISe for gpl20 binding, IIIB neutralizing titer, and activity in blocking HIV-1 virion binding to CD4+ cells (Fig. 6) . Anti-gpl20 antibodies reached maximum levels between 7 and 10 months after seroconversion, whereas the ISe-competing activity was substantially delayed, only reaching peak levels at 12 to 15 months. More (22) . Briefly, recombinant CHO gp120 (Celltech) was captured on solid phase by using antibody D7324. 15e was biotinylated by the standard protocol, and the concentration required for half-maximal binding was used, along with increasing concentrations of the competing antibody. Detection of bound ISe was achieved by adding streptavadin-alkaline phosphatase, followed by the use of the AMPAK ELISA amplification system. identified by ISe is a conformation-dependent ( Fig. 1C and  4) , previously unrecognized site important in CD4 binding (Fig. 1B and 3 ) and virus neutralization (Fig. 2) . It is distinct from the putative binding site defined by several groups (4, 17, 30 (11, 30) , which was based on that of McDougal et al. (19) ; neutralizing titer against the IIIB isolate was measured by our standard assay (11, 12, 30) . Similar kinetics for anti-gp120 antibody development were obtained at serum dilutions of 1:1,000, which was not saturating in the assay. (23) have found that the CD4-binding site may be formed by the juxtaposition of the third and fourth conserved domains of gpl20. It will be important to examine the possibility that ISe is directed against such a conformational determinant.
ISe neutralized multiple laboratory and primary HIV-1 isolates in vitro with variable potency (Fig. 2) . It is as yet unclear whether the differential sensitivity to 15e neutralization is the result of differential affinity of the antibody for various gpl20 molecules or, alternatively, of differential affinity of the gpl20 molecules for the CD4 receptor. Although 3 of 16 isolates tested were completely refractory to neutralization by 15e (up to 20 ,ug), the epitope identified by this human monoclonal antibody appears to be reasonably well conserved. Attempts should be made to preserve this conformational epitope in candidate gpl20 or gpl60 subunit vaccines. Given the slow development of 15e-like antibodies in HIV-1-infected persons ( Fig. 5C and 6) , prolonged immunization may be necessary to induce antibodies to the ISe epitope, unless the immunogenicity of this domain can be enhanced. Finally, if the concept of passive immunotherapy is proven efficacious in patients, ISe will be an excellent candidate for clinical use.
